Invo Fertility Inc. reported an unregistered sale of equity securities on July 28, 2025. An institutional investor and existing holder of Series C-2 Convertible Preferred Stock exercised its Additional Investment Right to acquire 200 shares of C-2 Preferred Stock, with an aggregate stated value of $200,000, for $200,000 in cash. The conversion price on the C-2 Preferred adjusted to $1.8909 per share. The transaction was conducted in reliance on exemptions from registration under the Securities Act.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.